A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

Clinical trial NCT05662397 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05662397
Sponsor: HotSpot Therapeutics, Inc
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Solid Tumor, Adult Relapsed Cancer Refractory Cancer

Start date: 2023-03-15
Primary completion: 2025-12-31
Enrollment: 77

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.